Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2022-04-21 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司董事会工作条例（2022年4月修订）
Governance Information Classification · 95% confidence The document is titled '董事会工作条例' which translates to 'Board of Directors Work Rules' or 'Board of Directors Regulations'. It details the structure, duties, meeting procedures, and governance of the company's board of directors. It includes sections on board composition, director qualifications, meeting notifications, voting procedures, and responsibilities. There is no financial data, no audit or financial report content, no earnings or capital update, no voting results, no legal proceedings, no merger or acquisition information, and no presentation or transcript. The document is a governance-related internal regulation document describing the board's rules and procedures. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not a Regulatory Filing or Report Publication Announcement. Confidence is high due to the clear focus on board governance rules and procedures.
2022-04-21 Chinese
金宇生物技术股份有限公司关于修订《公司章程》及相关治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from a company about revisions to its Articles of Association (公司章程) and related governance documents such as the Shareholders' Meeting Rules, Board of Directors Rules, Investment Management Measures, and President's Work Rules. It includes specific changes to governance structures, decision-making authorities, and procedural rules. The document is not a financial report, earnings release, or audit report. It is not a simple announcement of voting results or a proxy solicitation. Instead, it is a governance-related disclosure about internal rules and corporate governance practices. Therefore, the document fits best under the category 'Governance Information' (CGR). The document length and detail support this classification with high confidence.
2022-04-21 Chinese
金宇生物技术股份有限公司关于董事会、监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and nomination of the company's board of directors and supervisory board members. It details the candidates, their qualifications, and the process for the upcoming board and supervisory board elections. There is no financial data, no mention of financial results, nor is it a report or presentation. It is clearly an announcement about changes in the company's board and senior management structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3621 characters, which is consistent with an announcement rather than a full report.
2022-04-21 Chinese
金宇生物技术股份有限公司2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report explicitly states it is unaudited and includes comprehensive financial metrics and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document length is over 11,000 characters and contains substantive financial data, not just an announcement or certification. Therefore, the correct classification is IR. Q1 2022
2022-04-21 Chinese
金宇生物技术股份有限公司第十届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 10th Board of Directors of 金宇生物技术股份有限公司 (Jinyu Biotechnology Co., Ltd.). It includes approvals of various reports such as the 2021 Annual Report, 2022 Q1 Report, 2021 Board Work Report, profit distribution plan, internal control evaluation report, asset impairment provisions, independent directors' reports, audit committee reports, and other governance matters. It also includes nominations for the next board and amendments to company bylaws. The document is a formal record of board meeting decisions rather than the full reports themselves. It references that full reports and announcements are available on the Shanghai Stock Exchange website with separate announcement numbers. The document length is about 5,355 characters, which is relatively short for full annual or quarterly reports. This fits the pattern of a Board/Management Information filing, which covers announcements of board decisions and management matters. Therefore, the appropriate classification is MANG (Board/Management Information).
2022-04-21 Chinese
金宇生物技术股份有限公司关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of idle funds for cash management, detailing the investment amount, types of financial products, risk control measures, and board approval. It is a formal disclosure about financing activities but does not contain financial statements or results. It is not a full financial report, earnings release, or management discussion. The content fits the category of Capital/Financing Update (CAP) as it relates to the company's financing and cash management activities.
2022-04-21 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.